5 Enhanced glycemic control can be achieved with glucagon-like peptide-1 (GLP-1) receptor agonists, recommended by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as a first-line treatment option for individuals with T2DM with or at high risk for cardiovascular disease, heart failure, and/or chronic kidney disease
BPC-157 / TB-500 Research Grade Peptide Blend (5 mg + 5 mg) BPC-157 and TB-500 (Thymosin Beta-4) are synthetic peptides supplied together in a research-grade blend intended exclusively for controlled laboratory and in-vitro research environments
Animal studies, such as those summarized in a review on GLP1RA use in pregnancy, show concerning outcomes including fetal growth restriction and skeletal malformations
Its primary distinction is its dual-pathway mechanism (VEGFR2 + NO) combined with its gastric stability making it the only compound in this group with demonstrated activity when administered orally in animal models, not just by injection
For some patients, thats enough to maintain target
